North Bay rare disease drug developer wins 2nd drug approval in 2 weeks

Ultragenyx Pharmaceutical Inc. won its second drug approval in two weeks — and a month ahead of schedule — as regulators greenlighted a treatment against a family of debilitating and potentially deadly genetic disease. The Novato-based company (NASDAQ: RARE) said a 500-milliliter bottle of the drug to treat long-chain fatty acid oxidation disorders will cost $4,875 wholesale, or an average net price of $138,000 per patient per year. Because the disorders can occur in newborns, Ultragenyx said…

Click to view original post